pi3 kinase pathway
Recently Published Documents


TOTAL DOCUMENTS

105
(FIVE YEARS 5)

H-INDEX

29
(FIVE YEARS 2)

2020 ◽  
Author(s):  
Kelly H. Forest ◽  
Ruth Taketa ◽  
Komal Arora ◽  
Cedomir Todorovic ◽  
Robert A. Nichols

AbstractAlzheimer’s disease (AD) is the most common cause of dementia in the aging population. Evidence implicates elevated soluble oligomeric Aβ as one of the primary triggers during the prodromic phase leading to AD, effected largely via hyperphosphorylation of the microtubule-associated protein tau. At low, physiological levels (pM-nM), however, oligomeric Aβ has been found to regulate synaptic plasticity as a neuromodulator. Through mutational analysis, we found a core hexapeptide sequence within the N-terminal domain of Aβ (N-Aβcore) accounting for its physiological activity, and subsequently found that the N-Aβcore peptide is neuroprotective. Here, we characterized the neuroprotective potential of the N-Aβcore against dysfunction of synaptic plasticity assessed in ex vivo hippocampal slices from 5×FAD APP/PS1 mice, specifically hippocampal long-term potentiation (LTP) and long-term depression (LTD). The N-Aβcore was shown to reverse impairment in synaptic plasticity in hippocampal slices from 5×FAD APP/PS1 model mice, both for LTP and LTD. The reversal by the N-Aβcore correlated with alleviation of downregulation of hippocampal AMPA-type glutamate receptors in preparations from 5×FAD mice. The action of the N-Aβcore depended upon a critical di-histidine sequence and involved the PI3 kinase pathway via mTOR. Together, the present findings indicate that the non-toxic N-Aβcore hexapeptide is not only neuroprotective at the cellular level but is able to reverse synaptic dysfunction in AD-like models, specifically alterations in synaptic plasticity.


Blood ◽  
2019 ◽  
Vol 134 (Supplement_1) ◽  
pp. 5443-5443
Author(s):  
Yandong Shen ◽  
Kyle R Crassini ◽  
Narjis Fatima ◽  
Richard Christopherson ◽  
Stephen P. Mulligan ◽  
...  

Background The PI3-kinase signaling pathway and the Bcl-2-family of proteins play crucial roles in regulating the survival and proliferation of chronic lymphocytic leukemia (CLL) cells in the bone marrow and lymph nodes. Trials of ibrutinib, idelalisib and venetoclax illustrate the potential of targeting the B-cell receptor (BCR) signaling pathway and Bcl-2, however disease relapse is still common. Several pre-clinical studies and on-going clinical trials [Rogers et al., 2018, Jain et al., 2019] suggest that combinations of BCR inhibitors with venetoclax may be an effective treatment strategy for CLL patients with high risk disease. We sought to investigate the effects of combining idelalisib or the AKT inhibitor MK2206 with venetoclax against CLL cells under in vitro conditions that mimic the tumor microenvironment. Methods Primary CLL cells were co-cultured with CD40L-expressing mouse L-fibroblasts. Cell viability was assessed using the mitochondrial membrane potential dye DilC1(5), propidium iodide and flow cytometry (n = 6). Synergy between idelalisib or MK2206 and venetoclax was evaluated by calculating combination indices (CI) using the Compusyn software. The mechanisms of action of the drugs and synergies between the drugs were investigated by immunoblotting (n = 6). Results Venetoclax was highly synergistic in combination with idelalisib or MK2206 against CLL cells co-cultured with CD40L-fibroblasts, with CI values of 0.2 and 0.5 at a fractional effect of 0.9, respectively (Figure 1). This synergy was consistent with a significant (P < 0.05) reduction in the IC50 for venetoclax, idelalisib and MK2206. Immunoblotting suggests that MK2206, as a single agent or in combination with venetoclax, was more effective than idelalisib in inhibiting the phosphorylation of AKT and NF-κB. Both MK2206 and idelalisib as single agents and in combination with venetoclax significantly reduced expression of Mcl-1 and Bfl-1, two pro-survival members of the Bcl-2 family of proteins in primary CLL cells co-cultured with CD40L-fibroblasts. Conclusions The synergy observed, which was associated with a significant decrease in the IC50s for idelalisib and MK2206, may mitigate some of the toxicities associated with PI3-kinase pathway inhibitors. Comparison of the two PI3-kinase-pathway inhibitors suggests that MK2206 may be more effective than idelalisib at blocking BCR-mediated signaling as a single agent and in combination with venetoclax. The mechanisms underlying the synergy include down-regulation of expression of Bcl-2 family proteins that are not targeted by venetoclax as a single agent. The data presented support the rationale for on-going and future clinical trials of combination therapies incorporating a PI3-kinase inhibitor with venetoclax for the treatment of high risk CLL. Figure 1 Disclosures No relevant conflicts of interest to declare.


2019 ◽  
Vol 10 (1) ◽  
Author(s):  
Mike R. Wilson ◽  
Jake J. Reske ◽  
Jeanne Holladay ◽  
Genna E. Wilber ◽  
Mary Rhodes ◽  
...  

Head & Neck ◽  
2018 ◽  
Author(s):  
Mohammad Y. Ibrahim ◽  
Maria I. Nunez ◽  
Nusrat Harun ◽  
J. Jack Lee ◽  
Adel K. El‐Naggar ◽  
...  

2018 ◽  
Vol 20 (suppl_6) ◽  
pp. vi50-vi50
Author(s):  
Kensuke Tateishi ◽  
Taishi Nakamura ◽  
Alexandria Fink ◽  
Nina Lelic ◽  
Yuko Matsushita ◽  
...  

2018 ◽  
Author(s):  
Cristina Cristofoletti ◽  
Antonella Bresin ◽  
Mario Picozza ◽  
Maria Cristina Picchio ◽  
Francesca Passarelli ◽  
...  

2017 ◽  
Vol 19 (suppl_4) ◽  
pp. iv43-iv43
Author(s):  
Xiaochong Wu ◽  
Michael Taylor

Sign in / Sign up

Export Citation Format

Share Document